Metoprolol Vp (Metoprolol Tartrate)

Metoprolol is a selective β1‑adrenergic blocker used in several cardiovascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion.
• Heart failure: improves survival and reduces hospitalisation by decreasing cardiac workload.
• Acute myocardial infarction: limits infarct size and prevents recurrent ischemic events.
• Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

• Metoprolol selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation. This reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower oxygen consumption. The drug’s action is largely confined to the heart, sparing β2 receptors in the lungs and peripheral vasculature, which helps limit bronchial and vascular side effects.

Metoprolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Fatigue or general weakness.
• Dizziness or light‑headedness, especially on standing.
• Bradycardia (slow heart rate).
• Cold extremities or peripheral vasoconstriction.
• Gastrointestinal upset such as nausea or abdominal discomfort.
• Headache.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Marked hypotension leading to fainting.
• Bronchospasm in patients with underlying airway disease.
• Allergic reactions including rash, pruritus, or angio‑edema.
• Depression or mood changes.
• Worsening of heart failure symptoms.

Before initiating Metoprolol, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Cardiovascular assessment: verify baseline heart rate and blood pressure.
• Respiratory disease: use cautiously in patients with asthma or chronic obstructive pulmonary disease.
• Diabetes: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms.
• Hepatic or renal impairment: dose adjustments may be required.
• Concomitant AV‑nodal blockers: assess for additive bradycardic effects.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metoprolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Verapamil or diltiazem: combined use may cause profound bradycardia or heart block.
• Clonidine withdrawal: abrupt cessation while on Metoprolol can precipitate severe hypertension.
• Non‑selective beta‑blockers: additive β‑blockade may increase risk of cardiovascular depression.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive effect; monitor electrolytes and blood pressure.
• NSAIDs: can reduce antihypertensive efficacy.
• Antidepressants (e.g., SSRIs): may increase plasma Metoprolol levels.
• Antidiabetic agents: monitor glucose as β‑blockade can mask hypoglycaemia.
• Calcium channel blockers (non‑dihydropyridine): watch for additive cardiac effects.